Partner Therapeutics’ Bizengri is now FDA approved for treating advanced cases of cholangiocarcinoma driven by NRG1 gene fusions. Partner acquired U.S. rights to this bispecific antibody from Merus in 2024.
The post A Cancer Driven by Ultra-Rare Mutation Gets Its First FDA-Approved Therapy appeared first on MedCity News.
